NIH GPRA Scientific Research Outcomes Goals Matrix

+----------------------------------------+-----------------------------+
| No. of SROs:                           | No. of CTRs: 5              |
+----------------------------------------+-----------------------------+
| > No. of Extramural: 31                | No. of CBRRs: 8             |
+----------------------------------------+-----------------------------+
| > No. of Intramural: 7                 | No. of SMHCs: 6             |
+----------------------------------------+-----------------------------+
| > No. of Extra & Intra Combined: 13    | No. of POIs: 6              |
+----------------------------------------+-----------------------------+

+----+---------------+---------------------------+---------------------+
| Di | 1-3 Years     | 4-6 Years                 | 7-10 Years          |
| ff |               |                           |                     |
| ic |               |                           |                     |
| ul |               |                           |                     |
| ty |               |                           |                     |
+====+===============+===========================+=====================+
| Hi | > **1.1** By  | > **2.1** By 2015,        | **3.1** By 2013,    |
| gh | > 2008,       | > evaluate islet          | identify at least   |
|    | > conduct     | > transplantation in      | one clinical        |
|    | > medications | > combination with immune | intervention that   |
|    | > development | > modulation strategies   | will delay the      |
|    | > using       | > for the treatment of    | progression, delay  |
|    | > animal      | > type 1diabetes in       | the onset, or       |
|    | > models and  | > clinical trials**.**    | prevent Alzheimer's |
|    | > begin       | >                         | disease (AD).       |
|    | > conducting  | > **2.2** By 2009,        |                     |
|    | > Phase I and | > evaluate the efficacy   | **3.2** By 2010,    |
|    | > II trials   | > of two novel approaches | develop one         |
|    | > of two      | > to prevent weight gain  | universal           |
|    | > potential   | > and/or treat obesity in | antibiotic          |
|    | > treatments  | > clinical trials in      | effective against   |
|    | > for         | > humans.                 | multiple classes of |
|    | > alcoholism: | >                         | biological          |
|    | > the         | > 2.4 By 2009, develop    | pathogens.          |
|    | > cannabinoid | > and test                |                     |
|    | > antagonist  | > multidisciplinary       | **3.3** By 2013,    |
|    | > rimonabant  | > biobehavioral           | determine the       |
|    | > and the     | > interventions to        | efficacy of using   |
|    | > corticotro  | > prevent/attenuate       | salivary            |
|    | pin-releasing | > disease- and            | diagnostics to      |
|    | > hormone     | > treatment-related       | monitor health and  |
|    | > antagonist  | > symptoms such as pain,  | diagnose at least   |
|    | > antalarmin. | > fatigue, and            | one systemic        |
|    | >             | > psychological distress, | disease.            |
|    | > **1.3** By  | > to reduce related       |                     |
|    | > 2010,       | > symptom burden and to   | 3.4 By 2010,        |
|    | > develop an  | > increase functional     | develop an HIV/AIDS |
|    | >             | > status and quality of   | vaccine.            |
|    |  experimental | > life.                   |                     |
|    | > robotic     | >                         | 3.5 By 2013,        |
|    | > exoskeleton | > 2.5 By 2011, identify   | identify and        |
|    | > that can be | > and evaluate 5 novel    | characterize at     |
|    | > tested for  | > molecular-targeted      | least 2 human       |
|    | > clinical    | > interventions for       | candidate genes     |
|    | > r           | > cancer, and determine   | that have been      |
|    | ehabilitation | > suitability for use in  | shown to influence  |
|    | > of upper    | > early phase clinical    | risk for substance  |
|    | > extremity   | > trials.                 | use disorders and   |
|    | > movement.   | >                         | risk for            |
|    | >             | > **2.6** By 2011,        | psychiatric         |
|    | > **1.4** By  | > develop one field       | disorders using     |
|    | > 2012,       | > deployable sensor       | high-risk family,   |
|    | > identify    | > device for use in human | twin, and special   |
|    | > signatures  | > studies and develop one | population studies. |
|    | > of gene     | > biomarker to            |                     |
|    | > expression  | > characterize the impact | 3.6 By 2012,        |
|    | > in          | > of environmental        | develop and apply   |
|    | > peripheral  | > exposures on biological | clinically one new  |
|    | > tissues     | > pathways.               | imaging technique   |
|    | > that are    | >                         | to enable tracking  |
|    | > associated  | > **2.7** By 2011,        | the mobility of     |
|    | > with        | > complete clinical       | stem cells within   |
|    | > al          | > testing of one          | cardiovascular      |
|    | cohol-induced | > candidate medical       | tissues.            |
|    | > disorders.  | > countermeasure that     |                     |
|    |               | > could be used to        | 3.7 By 2019,        |
|    |               | > diagnose or treat       | develop at least    |
|    |               | > victims of a chemical   | two novel therapies |
|    |               | > terrorist attack or     | for immune-mediated |
|    |               | > accident, and complete  | disease.            |
|    |               | > preclinical testing for |                     |
|    |               | > two others.             | **3.8** By 2016,    |
|    |               | >                         | determine the       |
|    |               | > **2.8** By 2013,        | tailored treatment  |
|    |               | > advance two emerging    | regimen             |
|    |               | > new strategies for      | for patients with   |
|    |               | > treating muscular       | early stage cancer  |
|    |               | > dystrophy to the point  | that maximizes the  |
|    |               | > of preparedness for     | benefits of         |
|    |               | > clinical trials.        | chemotherapy while  |
|    |               |                           | minimizing the      |
|    |               |                           | side-effects of     |
|    |               |                           | unnecessary         |
|    |               |                           | treatment.          |
+----+---------------+---------------------------+---------------------+
| Me | **4.3** By    | **5.2** By 2009,          | **6.1** By 2012,    |
| di | 2009,         | determine the efficacy of | identify the genes  |
| um | evaluate the  | statins in preventing     | that control the    |
|    | safety and    | progression of            | risk of development |
|    | efficacy of   | atherosclerosis in        | of age-related      |
|    | two new       | children with systemic    | macular             |
|    | treatments    | lupus erythematosus (SLE, | degeneration (AMD)  |
|    | for           | or lupus).                | and glaucoma in     |
|    | nonalcoholic  |                           | humans.             |
|    | st            | **5.3** By 2009, expand   |                     |
|    | eatohepatitis | the range of available    | **6.2** By 2011,    |
|    | (NASH) in     | methods used to create,   | assess the efficacy |
|    | adults.       | analyze, and utilize      | of at least three   |
|    |               | chemical libraries, which | new treatment       |
|    | **4.4** By    | can be used to discover   | strategies to       |
|    | 2011,         | new medications.          | reduce              |
|    | identify or   | Specifically, use these   | cardiovascular      |
|    | study         | chemical libraries to     | morbidity/mortality |
|    | additional    | discover 10 new and       | in patients with    |
|    | genes         | unique chemical           | type 2 diabetes     |
|    | involved in   | structures that could     | and/or chronic      |
|    | communication | serve as the starting     | kidney disease.     |
|    | disorders in  | point for new drugs.      |                     |
|    | humans and    |                           | 6.3 By 2008,        |
|    | animal        | **5.5** By 2008, develop  | develop a knowledge |
|    | models.       | and test two new          | base on chemical    |
|    |               | evidence-based treatment  | effects in          |
|    | **4.5** By    | approaches for drug abuse | biological systems  |
|    | 2011,         | in community settings.    | using a systems     |
|    | identify      |                           | toxicology or       |
|    | genetic and   | **5.6** By 2009, identify | toxicogenomics      |
|    | environmental | 1 or 2 new medication     | approach.           |
|    | factors which | candidates to further     |                     |
|    | predispose to | test and develop for the  | **6.4** By 2014,    |
|    | three complex | treatment of tobacco      | identify and        |
|    | diseases.     | addiction.                | characterize two    |
|    |               |                           | molecular pathways  |
|    |               | **5.7** By 2010, validate | of potential        |
|    |               | and compare 3 imaging     | clinical            |
|    |               | methods that could offer  | significance that   |
|    |               | increased sensitivity     | may serve as the    |
|    |               | over computed tomography  | basis for           |
|    |               | (CT) as a means of        | discovering new     |
|    |               | assessing lung cancer     | medications for     |
|    |               | response to therapy.      | preventing and      |
|    |               |                           | treating asthma     |
|    |               | **5.8** By 2012, improve  | exacerbations.      |
|    |               | device(s) to measure hot  |                     |
|    |               | flashes and test in       | **6.5** By 2014,    |
|    |               | clinical trials of hot    | develop and         |
|    |               | flash therapies.          | evaluate two new    |
|    |               |                           | interventions for   |
|    |               | 5.9 By 2010, establish    | the prevention      |
|    |               | the role of genetic       | and/or treatment of |
|    |               | factors in three major    | HIV disease         |
|    |               | diseases for which health | utilizing the newly |
|    |               | disparities are noted     | restructured        |
|    |               | between populations.      | HIV/AIDS clinical   |
|    |               |                           | trials networks.    |
|    |               | **5.10** By 2011, conduct |                     |
|    |               | studies of girls aged 6   | **6.6** By 2015,    |
|    |               | through 8 years to        | provide at least    |
|    |               | determine the             | one new or          |
|    |               | associations between the  | significantly       |
|    |               | age of onset of puberty   | improved            |
|    |               | and progression through   | minimally-invasive  |
|    |               | puberty with 12           | treatment for       |
|    |               | environmental exposures.  | patients using      |
|    |               |                           | image-guided        |
|    |               | **5.11** By 2012, develop | interventions.      |
|    |               | and test at least two     |                     |
|    |               | behavioral strategies for |                     |
|    |               | the management of         |                     |
|    |               | symptoms to reduce the    |                     |
|    |               | effects of disease,       |                     |
|    |               | disability, or            |                     |
|    |               | psychological distress on |                     |
|    |               | quality of life and       |                     |
|    |               | outcomes.                 |                     |
|    |               |                           |                     |
|    |               | **5.12** By 2013,         |                     |
|    |               | identify several          |                     |
|    |               | potential targets and/or  |                     |
|    |               | molecules that modulate   |                     |
|    |               | or enhance the extinction |                     |
|    |               | of learned behaviors and  |                     |
|    |               | conditioned associations  |                     |
|    |               | supporting addiction,     |                     |
|    |               | compulsion, or anxiety    |                     |
|    |               | disorders.                |                     |
+----+---------------+---------------------------+---------------------+
| L  | **7.4** By    | **8.2** By 2009, identify | **9.1** By 2010,    |
| ow | 2009, create  | and characterize two      | demonstrate through |
|    | research      | molecular interactions of | research a capacity |
|    | resources to  | potential clinical        | to reduce the total |
|    | aid in the    | significance between      | years lost to       |
|    | i             | bone-forming cells and    | disability (YLDs)   |
|    | dentification | components of bone. Such  | in the United       |
|    | and           | interactions are defined  | States by 10% by    |
|    | evaluation of | as those having           | (1) developing      |
|    | biomarkers as | significant impact on the | treatment           |
|    | candidates    | accrual of bone mass or   | algorithms to       |
|    | for surrogate | the actual mechanical     | improve the         |
|    | endpoints for | performance of bone       | management of       |
|    | os            | (i.e., fracture           | treatment-resistant |
|    | teoarthritis. | resistance) in laboratory | and recurrent       |
|    |               | animals.                  | depression and (2)  |
|    | **7.5** By    |                           | elucidating the     |
|    | 2009,         | **8.4** By 2009, assess   | mechanisms by which |
|    | determine the | the impact of two major   | depression          |
|    | feasibility   | Institutional Development | influences at least |
|    | of applying   | Award (IDeA) Programs on  | two comorbid        |
|    | at least 2    | the development of        | physical illnesses  |
|    | tailored      | competitive investigators | (e.g., heart        |
|    | interventions | and their capacities to   | disease, cancer,    |
|    | designed to   | compete for NIH research  | Parkinson's         |
|    | prevent       | funding.                  | disease, or         |
|    | dental caries |                           | diabetes).          |
|    | in one or     | 8.5 By 2009, develop an   |                     |
|    | more          | item bank and             | **9.2** By 2018,    |
|    | underserved   | computerized adaptive     | identify culturally |
|    | populations.  | testing system available  | appropriate,        |
|    |               | to clinical researchers   | effective stroke    |
|    | **7.7** By    | to improve assessment of  | prevention programs |
|    | 2011, assess  | non-specific symptoms     | for nationwide      |
|    | co            | (e.g., pain and fatigue)  | implementation in   |
|    | mmunity-based | and other domains of      | minority            |
|    | methods for   | health-related quality of | communities.        |
|    | facilitating  | life in chronic disease.  |                     |
|    | cancer        |                           | 9.3 By 2011,        |
|    | research and  | 8.6 By 2011, extend the   | characterize the    |
|    | providing     | vision component of the   | progression of      |
|    | patients      | National Health and       | normal, healthy     |
|    | access to     | Nutrition Examination     | brain development   |
|    | optimal       | Survey (NHANES) to        | in a nationally     |
|    | cancer care.  | develop stable national   | representative      |
|    |               | estimates of vision       | sample of children  |
|    |               | impairment.               | in the United       |
|    |               |                           | States by creating  |
|    |               | **8.7** By 2012, identify | a database of MRI   |
|    |               | 3 effective               | and                 |
|    |               | implementation strategies | clinical/behavioral |
|    |               | that enhance the uptake   | data and analytical |
|    |               | of research-tested        | software.           |
|    |               | interventions in service  |                     |
|    |               | systems such as primary   | **9.4** By 2013,    |
|    |               | care, specialty care and  | develop and         |
|    |               | community practice.       | implement neonatal  |
|    |               |                           | screening for       |
|    |               | **8.8** By 2012, identify | congenital          |
|    |               | at least one candidate    | cytomegalovirus     |
|    |               | intervention that extends | (CMV) infection to  |
|    |               | median lifespan in an     | permit              |
|    |               | animal model.             | identification of   |
|    |               |                           | infants who will    |
|    |               |                           | develop CMV-induced |
|    |               |                           | hearing loss in the |
|    |               |                           | first years of      |
|    |               |                           | life.               |
|    |               |                           |                     |
|    |               |                           | **9.5** By 2014,    |
|    |               |                           | assess the efficacy |
|    |               |                           | of long-term oxygen |
|    |               |                           | treatment in        |
|    |               |                           | patients with COPD  |
|    |               |                           | and moderate        |
|    |               |                           | hypoxemia.          |
+----+---------------+---------------------------+---------------------+

**NIH GPRA Non-Scientific Research Outcomes Goals Matrix**

  -----------------------------------------------------------------------
  **Communication and Transfer of Results**

  CTR-1 By 2014, reduce the disparity between African American and white
  infants in back sleeping by 50% to further reduce the risk of Sudden
  Infant Death Syndrome (SIDS).

  CTR-4 By 2008, increase the percentage of SBIR award recipients who are
  successful in identifying the resources and/or partners necessary to
  further the development of their SBIR projects toward
  commercialization.

  CTR-6 By 2010, improve the efficiency and reduce the unit cost of
  producing authoritative serials cataloging records used to improve
  access to the biomedical literature in libraries worldwide.

  CTR-7 By 2010, establish the feasibility of sharing information from
  already-conducted scientific studies of warfarin (coumadin^R^)
  anti-coagulation, through the knowledge base PharmGKB.

  CTR-8 By 2012, improve communications efforts and enhance outreach
  strategies regarding extramural research funding policy, compliance and
  administration as demonstrated by the type and frequency of
  communications and related activities.
  -----------------------------------------------------------------------

  -----------------------------------------------------------------------
  **Capacity Building and Research Resource**
  -----------------------------------------------------------------------
  CBRR-1 By 2012, recruit, train, and retain a diverse population of
  highly trained scientists in biomedical, behavioral, and clinical
  research using research training grants, fellowships, career
  development awards, and student loan repayment programs.

  CBRR-2 Promote data sharing and provide information in real time by
  implementing and monitoring the NIH Business System. (By FY2010, the
  NBRSS will be in an ongoing status)

  CBRR-4 By 2013, provide greater functionality and more streamlined
  processes in grants administration by continuing to develop the NIH
  electronic Research Administration (eRA) system.

  CBRR-6 By 2010, build capacity to conduct research by constructing or
  renovating extramural facilities to meet the biomedical and behavioral
  research, research training or research support needs.

  CBRR-7 By 2010, utilize enhanced ARIS database to more efficiently
  conduct portfolio analysis to invest in priority AIDS research.

  CBRR-8 By 2012, ensure that 100% of trainee appointment forms are
  processed electronically, to enhance program management.

  CBRR-9 By 2010, achieve average annual cost savings of managing
  construction grants by expanding the use of electronic project
  management tools that enhance oversight and 20 year usage monitoring.

  CBRR-10 By 2013, make freely available to researchers the results of
  300 high-throughput biological assays screened against a library of
  300,000 unique compounds, and the detailed information on the molecular
  probes that are developed through that screening process.
  -----------------------------------------------------------------------

  -----------------------------------------------------------------------
  **Strategic Management of Human Capital**

  SMHC-3 By 2008, improve the strategic management of NIH human resources
  by developing and monitoring a comprehensive human capital plan based
  on the Agency's programmatic objectives and projected future needs.

  SMHC-4 Ensure that NIH commercial functions are performed as
  efficiently and cost-effectively as possible by conducting competitive
  sourcing reviews on the required number of functions within the
  Agency's commercial inventory. (Ongoing)

  SMHC-5 Improve and monitor the use of human resource services by
  providing real-time access to tools via the NIH Portal. (Ongoing).

  SMHC-6 Provide opportunities for enhanced leadership skills to meet the
  challenges of workforce management and/or individual advancements.
  (Ongoing)

  SMHC-7 Address diverse workforce recruitment needs to ascertain highly
  qualified staff to conduct or support biomedical research. (Ongoing)

  SMHC-8 Address areas to facilitate retention of highly qualified staff
  to conduct or support biomedical research. (Ongoing)
  -----------------------------------------------------------------------

  -----------------------------------------------------------------------
  **Program Oversight and Improvement**

  POI-2 Utilize Performance Based Contracting (PBC). (Ongoing)

  POI-5 By 2010, enhance NIH\'s ability to demonstrate benefits for
  extramural research investments through changes to policy and
  information system.

  POI-6 Provide responsible stewardship over existing federally owned
  real property assets. (Ongoing)

  POI-7 Manage design and construction of capital facility projects
  funded by the Building and Facilities Appropriation (B&F) so that HHS
  and congressionally approved scope of work is delivered within the
  approved budget. (Ongoing)

  POI-8 By 2010, protect NIH\'s interest in real property supported under
  the extramural construction grant program by ensuring compliance with
  construction and 20 year usage requirements.

  POI-9 By 2012, reallocate laboratory resources based on external
  reviews by Boards of Scientific Counselors.
  -----------------------------------------------------------------------